Positron emission tomography (PET) is no better than single-photon emission computed tomography (SPECT) in the evaluation of ischemic heart disease, according to a technology assessment published by ECRI.The study, sponsored by the Plymouth Meeting,
Positron emission tomography (PET) is no better than single-photon emission computed tomography (SPECT) in the evaluation of ischemic heart disease, according to a technology assessment published by ECRI.
The study, sponsored by the Plymouth Meeting, PA-based nonprofit group, concluded that PET images provide better contrast and spatial resolution than SPECT in assessments of myocardial blood flow and viability. The group found that the difference had little effect on clinicians' ability to diagnose coronary artery disease, however.
The study concluded that there is some question as to when PET's expense and clinical value justify its use over SPECT. The study was prepared by ECRI's Health Technology Assessment Information Service.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.